Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.

Hiren Patel,Kamlesh Khunti,Helena W Rodbard,Harpreet S Bajaj,Ross Bray, Zbigniew Kindracki,Ángel Rodríguez

Diabetes, obesity & metabolism（2023）

引用 0|浏览2

暂无评分

摘要

Superior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs.

查看译文

关键词

diarrhoea, gastrointestinal adverse events, GIP and GLP-1 receptor agonist, incretin therapy, nausea, tirzepatide, type 2 diabetes, vomiting, weight loss

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要